• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

从头自组装肽介导替莫唑胺的转化并将一种模型药物递送至多形性胶质母细胞瘤细胞中。

De Novo Self-Assembling Peptides Mediate the Conversion of Temozolomide and Delivery of a Model Drug into Glioblastoma Multiforme Cells.

作者信息

Pitz Megan, Elpers Margaret, Nukovic Alexandra, Wilde Sarah, Gregory Arica Jordan, Alexander-Bryant Angela

机构信息

Nanobiotechnology Lab, Department of Bioengineering, Clemson University, Clemson, SC 29634, USA.

出版信息

Biomedicines. 2022 Sep 2;10(9):2164. doi: 10.3390/biomedicines10092164.

DOI:10.3390/biomedicines10092164
PMID:36140265
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC9495814/
Abstract

Glioblastoma multiforme (GBM) is the most aggressive central nervous system tumor, and standard treatment, including surgical resection, radiation, and chemotherapy, has not significantly improved patient outcomes over the last 20 years. Temozolomide (TMZ), the prodrug most commonly used to treat GBM, must pass the blood-brain barrier and requires a basic pH to convert to its active form. Due to these barriers, less than 30% of orally delivered TMZ reaches the central nervous system and becomes bioactive. In this work, we have developed a novel biomaterial delivery system to convert TMZ to its active form and that shows promise for intracellular TMZ delivery. Self-assembling peptides were characterized under several different assembly conditions and evaluated for TMZ loading and conversion. Both solvent and method of assembly were found to affect the supramolecular and secondary structure of peptide assemblies. Additionally, as peptides degraded in phosphate-buffered saline, TMZ was rapidly converted to its active form. This work demonstrates that peptide-based drug delivery systems can effectively create a local stimulus during drug delivery while remaining biocompatible. This principle could be used in many future biomedical applications in addition to cancer treatment, such as wound healing and regenerative medicine.

摘要

多形性胶质母细胞瘤(GBM)是最具侵袭性的中枢神经系统肿瘤,在过去20年里,包括手术切除、放疗和化疗在内的标准治疗方法并未显著改善患者的预后。替莫唑胺(TMZ)是最常用于治疗GBM的前体药物,它必须穿过血脑屏障,并且需要碱性pH才能转化为其活性形式。由于这些障碍,口服给药的TMZ只有不到30%到达中枢神经系统并具有生物活性。在这项工作中,我们开发了一种新型生物材料递送系统,可将TMZ转化为其活性形式,并显示出细胞内递送TMZ的前景。在几种不同的组装条件下对自组装肽进行了表征,并评估了TMZ的负载和转化情况。发现溶剂和组装方法都会影响肽组装体的超分子结构和二级结构。此外,随着肽在磷酸盐缓冲盐水中降解,TMZ迅速转化为其活性形式。这项工作表明,基于肽的药物递送系统可以在药物递送过程中有效地产生局部刺激,同时保持生物相容性。除癌症治疗外,这一原理还可用于许多未来的生物医学应用,如伤口愈合和再生医学。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1139/9495814/85f6911a226f/biomedicines-10-02164-g010.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1139/9495814/1368fbc6b696/biomedicines-10-02164-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1139/9495814/90b49db24ed6/biomedicines-10-02164-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1139/9495814/d9d6f2054a8e/biomedicines-10-02164-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1139/9495814/111980100b90/biomedicines-10-02164-g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1139/9495814/f96a545d7e82/biomedicines-10-02164-g005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1139/9495814/3d447cf3d669/biomedicines-10-02164-g006.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1139/9495814/849f9f734a81/biomedicines-10-02164-g007.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1139/9495814/02b99c53df0e/biomedicines-10-02164-g008.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1139/9495814/24d0a35756f7/biomedicines-10-02164-g009.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1139/9495814/85f6911a226f/biomedicines-10-02164-g010.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1139/9495814/1368fbc6b696/biomedicines-10-02164-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1139/9495814/90b49db24ed6/biomedicines-10-02164-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1139/9495814/d9d6f2054a8e/biomedicines-10-02164-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1139/9495814/111980100b90/biomedicines-10-02164-g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1139/9495814/f96a545d7e82/biomedicines-10-02164-g005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1139/9495814/3d447cf3d669/biomedicines-10-02164-g006.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1139/9495814/849f9f734a81/biomedicines-10-02164-g007.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1139/9495814/02b99c53df0e/biomedicines-10-02164-g008.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1139/9495814/24d0a35756f7/biomedicines-10-02164-g009.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1139/9495814/85f6911a226f/biomedicines-10-02164-g010.jpg

相似文献

1
De Novo Self-Assembling Peptides Mediate the Conversion of Temozolomide and Delivery of a Model Drug into Glioblastoma Multiforme Cells.从头自组装肽介导替莫唑胺的转化并将一种模型药物递送至多形性胶质母细胞瘤细胞中。
Biomedicines. 2022 Sep 2;10(9):2164. doi: 10.3390/biomedicines10092164.
2
Delivery of Temozolomide and N3-Propargyl Analog to Brain Tumors Using an Apoferritin Nanocage.载有替莫唑胺和 N3-炔丙基类似物的去铁铁蛋白纳米笼递送至脑肿瘤。
ACS Appl Mater Interfaces. 2020 Mar 18;12(11):12609-12617. doi: 10.1021/acsami.0c01514. Epub 2020 Mar 4.
3
Combination therapy in a xenograft model of glioblastoma: enhancement of the antitumor activity of temozolomide by an MDM2 antagonist.在胶质母细胞瘤的异种移植模型中进行联合治疗:MDM2 拮抗剂增强替莫唑胺的抗肿瘤活性。
J Neurosurg. 2017 Feb;126(2):446-459. doi: 10.3171/2016.1.JNS152513. Epub 2016 May 13.
4
A tumor-targeting p53 nanodelivery system limits chemoresistance to temozolomide prolonging survival in a mouse model of glioblastoma multiforme.一种肿瘤靶向性p53纳米递送系统可限制对替莫唑胺的化疗耐药性,延长多形性胶质母细胞瘤小鼠模型的生存期。
Nanomedicine. 2015 Feb;11(2):301-11. doi: 10.1016/j.nano.2014.09.005. Epub 2014 Sep 18.
5
Intranasal Delivery of Temozolomide-Conjugated Gold Nanoparticles Functionalized with Anti-EphA3 for Glioblastoma Targeting.经 EphA3 靶向抗体功能化的载替莫唑胺金纳米颗粒经鼻腔递药治疗脑胶质瘤。
Mol Pharm. 2021 Mar 1;18(3):915-927. doi: 10.1021/acs.molpharmaceut.0c00911. Epub 2021 Jan 8.
6
Encapsulation of temozolomide in a tumor-targeting nanocomplex enhances anti-cancer efficacy and reduces toxicity in a mouse model of glioblastoma.在胶质母细胞瘤小鼠模型中,将替莫唑胺包裹于肿瘤靶向纳米复合物中可增强抗癌疗效并降低毒性。
Cancer Lett. 2015 Dec 1;369(1):250-8. doi: 10.1016/j.canlet.2015.08.022. Epub 2015 Sep 2.
7
Dual-targeting immunoliposomes using angiopep-2 and CD133 antibody for glioblastoma stem cells.载有抗 Angiopep-2 和 CD133 抗体的双靶向免疫脂质体用于神经胶质瘤干细胞。
J Control Release. 2018 Jan 10;269:245-257. doi: 10.1016/j.jconrel.2017.11.026. Epub 2017 Nov 21.
8
Improving temozolomide biopharmaceutical properties in glioblastoma multiforme (GBM) treatment using GBM-targeting nanocarriers.使用脑胶质瘤靶向纳米载体改善替莫唑胺在多形性胶质母细胞瘤(GBM)治疗中的生物制药特性。
Eur J Pharm Biopharm. 2021 Nov;168:76-89. doi: 10.1016/j.ejpb.2021.08.011. Epub 2021 Aug 28.
9
Novel RGD containing, temozolomide-loading nanostructured lipid carriers for glioblastoma multiforme chemotherapy.用于多形性胶质母细胞瘤化疗的新型含RGD、载有替莫唑胺的纳米结构脂质载体
Drug Deliv. 2016 May;23(4):1404-8. doi: 10.3109/10717544.2015.1064186. Epub 2015 Jul 23.
10
Comparative analysis of the effects of a sphingosine kinase inhibitor to temozolomide and radiation treatment on glioblastoma cell lines.鞘氨醇激酶抑制剂与替莫唑胺及放疗对胶质母细胞瘤细胞系作用的比较分析
Cancer Biol Ther. 2017 Jun 3;18(6):400-406. doi: 10.1080/15384047.2017.1323583. Epub 2017 May 11.

引用本文的文献

1
Electrospun Drug-Loaded and Gene-Loaded Nanofibres: The Holy Grail of Glioblastoma Therapy?电纺载药和载基因纳米纤维:胶质母细胞瘤治疗的圣杯?
Pharmaceutics. 2023 Jun 3;15(6):1649. doi: 10.3390/pharmaceutics15061649.

本文引用的文献

1
Factors Affecting Secondary and Supramolecular Structures of Self-Assembling Peptide Nanocarriers.影响自组装肽纳米载体的二级和超分子结构的因素。
Macromol Biosci. 2022 Feb;22(2):e2100347. doi: 10.1002/mabi.202100347. Epub 2021 Nov 20.
2
DichroWeb, a website for calculating protein secondary structure from circular dichroism spectroscopic data.DichroWeb,一个用于根据圆二色性光谱数据计算蛋白质二级结构的网站。
Protein Sci. 2022 Jan;31(1):37-46. doi: 10.1002/pro.4153. Epub 2021 Jul 21.
3
Preclinical evaluation of binimetinib (MEK162) delivered via polymeric nanocarriers in combination with radiation and temozolomide in glioma.
聚合物纳米载体递送 binimetinib(MEK162)联合放疗和替莫唑胺治疗脑胶质瘤的临床前评价。
J Neurooncol. 2020 Jan;146(2):239-246. doi: 10.1007/s11060-019-03365-y. Epub 2019 Dec 24.
4
Codelivery of paclitaxel and temozolomide through a photopolymerizable hydrogel prevents glioblastoma recurrence after surgical resection.通过光聚合水凝胶共递送紫杉醇和替莫唑胺可防止手术切除后的胶质母细胞瘤复发。
J Control Release. 2019 Sep 10;309:72-81. doi: 10.1016/j.jconrel.2019.07.015. Epub 2019 Jul 12.
5
Recent advances of self-assembling peptide-based hydrogels for biomedical applications.基于自组装肽的水凝胶在生物医学中的最新进展。
Soft Matter. 2019 Feb 20;15(8):1704-1715. doi: 10.1039/c8sm02573h.
6
Tri-block copolymer nanoparticles modified with folic acid for temozolomide delivery in glioblastoma.载有替莫唑胺的三嵌段共聚物纳米粒经叶酸修饰用于治疗脑胶质瘤
Int J Biochem Cell Biol. 2019 Mar;108:72-83. doi: 10.1016/j.biocel.2019.01.010. Epub 2019 Jan 17.
7
Polymer-Temozolomide Conjugates as Therapeutics for Treating Glioblastoma.聚合物-替莫唑胺缀合物作为治疗胶质母细胞瘤的疗法。
Mol Pharm. 2018 Nov 5;15(11):5263-5276. doi: 10.1021/acs.molpharmaceut.8b00766. Epub 2018 Oct 15.
8
Chemotherapeutic Delivery from a Self-Assembling Peptide Nanofiber Hydrogel for the Management of Glioblastoma.自组装肽纳米纤维水凝胶用于胶质母细胞瘤治疗的化疗药物递送。
Pharm Res. 2018 Jun 25;35(8):166. doi: 10.1007/s11095-018-2442-1.
9
Receptor-mediated PLGA nanoparticles for glioblastoma multiforme treatment.受体介导的 PLGA 纳米粒用于多形性胶质母细胞瘤的治疗。
Int J Pharm. 2018 Jul 10;545(1-2):84-92. doi: 10.1016/j.ijpharm.2018.04.062. Epub 2018 Apr 30.
10
Local alkylating chemotherapy applied immediately after 5-ALA guided resection of glioblastoma does not provide additional benefit.局部烷化剂化疗在 5-ALA 引导下切除胶质母细胞瘤后立即应用并不能提供额外的益处。
J Neurooncol. 2018 Jan;136(2):273-280. doi: 10.1007/s11060-017-2649-8. Epub 2017 Nov 14.